Is Indium In 111 Pentetate safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Indium In 111 Pentetate. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Information in this record refers to the use of indium In 111 pentetate as a diagnostic agent. No information is available on the use of indium In 111 pentetate during breastfeeding. Because of the long half-life of indium 111 and the potential for serious adverse reactions in nursing infants, it is best to avoid the drug in women who wish to continue breastfeeding. If the drug is given, breastfeeding should be discontinued.
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Indium 111 decays by electron capture with 173 keV and 245 keV gamma emissions and a physical half-life of 2.8 days.[1] The manufacturer reports that 65% of the administered dose is excreted by the kidneys within 24 hours and 85% is excreted in 72 hours.
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Indium In 111 Pentetate” (LM1151). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.